Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells boost knee cartilage healing in new trial

NCT ID NCT07255547

Disease control Sponsor: Università degli Studi dell'Aquila Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding stem cells from fat tissue to platelet-rich plasma (PRP) improves healing after knee microfracture surgery for cartilage damage. Eighty adults with small knee cartilage injuries will receive either PRP alone or PRP plus stem cells during arthroscopy. Researchers will track pain, function, and side effects for up to 5 years to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich plasma (PRP) and adipose-derived stem cells (AD-SVF)
What this could lead to
If it works, this could lead to a better way to repair knee cartilage injuries, potentially reducing pain and improving function without major side effects.
What could go wrong
This is a small, early-phase trial with only 80 people, so results may not apply to everyone. Adding stem cells could increase risks like swelling or longer recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

80 people

The number who actually took part.

Started

May 2019

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * knee pain and functional limitation for at least three months, monocompartmental chondral lesion \< 2 cm2, age over 18, and BMI between 18.5 and 30 Exclusion Criteria: * previous major surgery on the same knee, concomitant chondral lesions in other knee compartments, being diagnosed with knee or hip osteoarthritis, knee instability, flexion deficit \> 20° or extension deficit \>15°, genu valgum or genu varum \> 20°, patients with Hb values \< 11 g/dL or platelet \< 150000/µL, patients in therapy with antiaggregants or anticoagulants or immunosuppressive agents, pregnancy, and the following comorbidities: hematological/neurologic/metabolic/rheumatic diseases, neoplastic disorders or history of local infections.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee chondral lesion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fractures, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee chondral lesion

Contacts and locations

Locations

  • San Salvatore Hospital

    L’Aquila, Abruzzo, 67100, Italy